01.11.2023 - Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including progress on its strategic transformation and a corresponding restructuring of operations and workforce reduction, and .
Sangamo Therapeutics (SGMO) Reports Q1, Provides Strategic Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Dosing of patients in Phase 3 AFFINE trial to support primary analysis complete; pivotal data read-out expected in mid-2024; BLA and MAA submissions anticipated in second half of 2024. . | April 26, 2023
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Strong clinical momentum continues in Phase 1/2 STAAR study in Fabry disease with 20 patients dosed in total.
Dosed third patient in cohort 1 of Phase 1/2 CAR-Treg STEADFAST study for TX200 in. | June 18, 2023